

List of CHRS Members Lead Very High Impact Publications

1. Sapp JL, Tang ASL, Parkash R, et al. [Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia](#). *N Engl J Med*.
2. Knops RE, Lloyd MS, Roberts PR, et al. [A Modular Communicative Leadless Pacing-Defibrillator System](#). *N Engl J Med*. 2024;391(15):1402-1412.
3. Oraii A, McIntyre WF, Parkash R, et al. [Atrial Fibrillation Ablation in Heart Failure With Reduced vs Preserved Ejection Fraction: A Systematic Review and Meta-Analysis](#). *JAMA Cardiol*. 2024;9(6):545-555.
4. Sapp JL, Sivakumaran S, Redpath CJ, et al. [Long-Term Outcomes of Resynchronization-Defibrillation for Heart Failure](#). *N Engl J Med*. 2024;390(3):212-220.
5. Healey JS, Lopes RD, Granger CB, et al. [Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation](#). *N Engl J Med*. 2024;390(2):107-117.
6. Johnson LS, Mente A, Joseph P, et al. [Sodium Intake and Incident Atrial Fibrillation in Individuals With Vascular Disease](#). *JAMA Netw Open*. 2024;7(7):e2421589.
7. Conen D, Ke Wang M, Popova E, et al. [Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery \(COP-AF\): an international randomised trial](#). *Lancet*. 2023;402(10413):1627-1635.
8. Wilkoff BL, Filippatos G, Leclercq C, et al. [Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure \(AdaptResponse\): a global, prospective, randomised controlled trial](#) [published correction appears in *Lancet*. 2023 Sep 30;402(10408):1132.
9. Boursalie S, MacIntyre C, Sapp JL, et al. [Disparities in Referral and Utilization of Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death](#). *Can J Cardiol*. 2023;39(11):1610-1616.
10. Andrade JG, Deyell MW, Macle L, et al. [Progression of Atrial Fibrillation after Cryoablation or Drug Therapy](#). *N Engl J Med*. 2023;388(2):105-116.
11. Han HC, Wang J, Birnie DH, et al. [Association of the Timing and Extent of Cardiac Implantable Electronic Device Infections With Mortality](#). *JAMA Cardiol*. 2023;8(5):484-491.
12. Nair GM, Birnie DH, Nery PB, et al. [Standard vs Augmented Ablation of Paroxysmal Atrial Fibrillation for Reduction of Atrial Fibrillation Recurrence: The AWARE Randomized Clinical Trial](#). *JAMA Cardiol*. 2023;8(5):475-483.

13. Force ZM, Parkash R, Tang A, et al. [Health Security Perceptions: Initial Psychometric Analysis of the Construct of Health Security in Chronic Illness Among Patients With a Cardiac Device](#). *CJC Open*. 2023;5(9):704-708.
14. Greene A, Sapp J, Hirsch G, et al. [Cardiovascular Outcomes in Nova Scotia During the Early Phase of the COVID-19 Pandemic](#). *CJC Open*. 2022;4(3):324-336.
15. Whitlock RP, Belley-Cote EP, Paparella D, et al. [Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke](#). *N Engl J Med*. 2021;384(22):2081-2091.
16. Andrade JG, Wells GA, Deyell MW, et al. [Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation](#). *N Engl J Med*. 2021;384(4):305-315.
17. Stiell IG, Eagles D, Nemnom MJ, et al. [Adverse Events Associated With Electrical Cardioversion in Patients With Acute Atrial Fibrillation and Atrial Flutter](#). *Can J Cardiol*. 2021;37(11):1775-1782.
18. Yee R, Karim SS, Bashir J, et al. [Canadian Heart Rhythm Society Task Force Report on Physician Training and Maintenance of Competency for Cardiovascular Implantable Electronic Device Therapies: Executive Summary](#). *Can J Cardiol*. 2021;37(11):1857-1860.
19. Gladstone DJ, Wachter R, Schmalstieg-Bahr K, et al. [Screening for Atrial Fibrillation in the Older Population: A Randomized Clinical Trial](#). *JAMA Cardiol*. 2021;6(5):558-567.
20. McIntyre WF, Wang MK, Conen D. [Balancing the Risks and Benefits of Oral Anticoagulant Use in Patients With Postoperative Atrial Fibrillation](#). *Can J Cardiol*. 2021;37(6):938.e11.
21. Andrade JG, Aguilar M, Atzema C, et al. [The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation](#). *Can J Cardiol*. 2020;36(12):1847-1948.
22. Samuel M, Khairy P, Mongeon FP, et al. [Pulmonary Vein Stenosis After Atrial Fibrillation Ablation: Insights From the ADVICE Trial](#). *Can J Cardiol*. 2020;36(12):1965-1974.
23. Andrade JG, Wells GA, Deyell MW, et al. [Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation](#). *N Engl J Med*. 2021;384(4):305-315.
24. Connolly SJ, Eikelboom JW, Bosch J, et al. [Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial](#). *Lancet*. 2018;391(10117):205-218.

25. Sapp JL, Wells GA, Parkash R, et al. [Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs](#). N Engl J Med. 2016;375(2):111-121.
26. Healey JS, Oldgren J, Ezekowitz M, et al. [Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study](#). Lancet. 2016;388(10050):1161-1169.
27. Verma A, Jiang CY, Betts TR, et al. [Approaches to catheter ablation for persistent atrial fibrillation](#). N Engl J Med. 2015;372(19):1812-1822.
28. Morillo CA, Marin-Neto JA, Avezum A, et al. [Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy](#). N Engl J Med. 2015;373(14):1295-1306.
29. Healey JS, Hohnloser SH, Glikson M, et al. [Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial \(SIMPLE\)](#). Lancet. 2015;385(9970):785-791.
30. Morillo CA, Verma A, Connolly SJ, et al. [Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation \(RAAFT-2\): a randomized trial](#). JAMA. 2014;311(7):692-700.
31. Eikelboom JW, Connolly SJ, Brueckmann M, et al. [Dabigatran versus warfarin in patients with mechanical heart valves](#). N Engl J Med. 2013; 369(13):1206-1214.
32. Birnie DH, Healey JS, Wells GA, et al. [Pacemaker or defibrillator surgery without interruption of anticoagulation](#). N Engl J Med. 2013;368(22):2084-2093.
33. Healey JS, Connolly SJ, Gold MR, et al. [Subclinical atrial fibrillation and the risk of stroke](#). N Engl J Med. 2012;366(2):120-129.
34. Investigators AI, Yusuf S, Healey JS, et al. [Irbesartan in patients with atrial fibrillation](#). N Engl J Med. 2011;364(10):928-938.
35. Connolly SJ, Eikelboom J, Joyner C, et al. [Apixaban in patients with atrial fibrillation](#). N Engl J Med. 2011;364(9):806-817.
36. Connolly SJ, Camm AJ, Halperin JL, et al. [Dronedarone in high-risk permanent atrial fibrillation](#). N Engl J Med. 2011;365(24):2268-2276.
37. Tang AS, Wells GA, Talajic M, et al. [Cardiac-resynchronization therapy for mild-to-moderate heart failure](#). N Engl J Med. 2010;363(25):2385-2395.
38. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L, Randomized Evaluation of Long-Term Anticoagulation Therapy I. [Newly identified events in the RE-LY trial](#). N Engl J Med. 2010;363(19):1875-1876.

39. Investigators A, Connolly SJ, Pogue J, et al. [Effect of clopidogrel added to aspirin in patients with atrial fibrillation](#). N Engl J Med. 2009;360(20):2066-2078.
40. Connolly SJ, Ezekowitz MD, Yusuf S, et al. [Dabigatran versus warfarin in patients with atrial fibrillation](#). N Engl J Med. 2009;361(12):1139-1151.
41. Investigators AWGotA, Connolly S, Pogue J, et al. [Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events \(ACTIVE W\): a randomised controlled trial](#). Lancet. 2006;367(9526):1903-1912.
42. Gould PA, Krahn AD, Canadian Heart Rhythm Society Working Group on Device A. [Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories](#). JAMA. 2006;295(16):1907-1911.
43. Gollob MH, Jones DL, Krahn AD, et al. [Somatic mutations in the connexin 40 gene \(GJA5\) in atrial fibrillation](#). N Engl J Med. 2006;354(25):2677-2688.
44. Connolly SJ, Dorian P, Roberts RS, et al. [Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial](#). JAMA. 2006;295(2):165-171.
45. Hohnloser SH, Kuck KH, Dorian P, et al. [Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction](#). N Engl J Med. 2004;351(24):2481-2488.
46. Connolly SJ, Sheldon R, Thorpe KE, et al. [Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study \(VPS II\): a randomized trial](#). JAMA. 2003;289(17):2224-2229.
47. Gollob MH, Green MS, Tang AS, et al. [Identification of a gene responsible for familial Wolff-Parkinson-White syndrome](#). N Engl J Med. 2001;344(24):1823-1831.
48. Cairns JA, Connolly SJ, Roberts R, Gent M. [Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT](#). Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet. 1997;349(9053):675-682.